Perrigo Return on Tangible Equity 2010-2025 | PRGO
Current and historical return on tangible equity values for Perrigo (PRGO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Perrigo Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $-0.18B | $-1.47B | 12.17% |
| 2024-12-31 | $-0.17B | $-1.43B | 11.23% |
| 2024-09-30 | $-0.16B | $-1.52B | 9.93% |
| 2024-06-30 | $-0.12B | $-1.46B | 7.46% |
| 2024-03-31 | $-0.01B | $-1.68B | 0.46% |
| 2023-12-31 | $-0.01B | $-1.75B | 0.72% |
| 2023-09-30 | $-0.01B | $-1.76B | 0.27% |
| 2023-06-30 | $-0.07B | $-1.84B | 3.59% |
| 2023-03-31 | $-0.14B | $-1.90B | 7.34% |
| 2022-12-31 | $-0.14B | $-1.94B | 9.81% |
| 2022-09-30 | $-0.11B | $-1.89B | 11.24% |
| 2022-06-30 | $-0.12B | $-1.96B | 23.67% |
| 2022-03-31 | $-0.11B | $0.08B | -337.98% |
| 2021-12-31 | $-0.07B | $0.00B | -148.39% |
| 2021-09-30 | $-0.25B | $-0.08B | -396.88% |
| 2021-06-30 | $-0.35B | $0.13B | 236.49% |
| 2021-03-31 | $-0.23B | $0.13B | 53.07% |
| 2020-12-31 | $-0.16B | $0.07B | 20.96% |
| 2020-09-30 | $-0.01B | $-0.93B | 0.62% |
| 2020-06-30 | $0.24B | $-1.02B | -19.34% |
| 2020-03-31 | $0.19B | $-1.24B | -15.45% |
| 2019-12-31 | $0.15B | $-1.30B | -12.46% |
| 2019-09-30 | $0.25B | $-1.41B | -21.46% |
| 2019-06-30 | $0.09B | $-0.92B | -7.68% |
| 2019-03-31 | $0.11B | $-1.06B | -9.10% |
| 2018-12-31 | $0.13B | $-1.22B | -9.87% |
| 2018-09-30 | $0.12B | $-1.34B | -8.91% |
| 2018-06-30 | $0.24B | $-1.40B | -16.50% |
| 2018-03-31 | $0.13B | $-1.35B | -8.83% |
| 2017-12-31 | $0.12B | $-1.39B | -8.08% |
| 2017-09-30 | $-1.31B | $-1.56B | 61.66% |
| 2017-06-30 | $-2.95B | $-1.55B | 102.51% |
| 2017-03-31 | $-3.41B | $-1.45B | 91.21% |
| 2016-12-31 | $-4.01B | $-3.95B | 84.24% |
| 2016-09-30 | $-2.83B | $-4.55B | 55.59% |
| 2016-06-30 | $-0.98B | $-5.01B | 18.85% |
| 2016-03-31 | $-0.46B | $-5.54B | 9.11% |
| 2015-12-31 | $0.04B | $-5.25B | -1.13% |
| 2015-09-30 | $0.29B | $-4.91B | -11.04% |
| 2015-06-30 | $0.12B | $-4.68B | -7.02% |
| 2014-12-31 | $0.21B | $-0.40B | -15.86% |
| 2014-09-30 | $0.06B | $-1.46B | -3.33% |
| 2013-12-31 | $0.14B | $-1.98B | -32.66% |
| 2013-09-30 | $0.33B | $0.14B | 219.33% |
| 2012-12-31 | $0.33B | $0.30B | 107.19% |
| 2012-09-30 | $0.32B | $0.43B | 129.58% |
| 2011-12-31 | $0.26B | $0.07B | 185.66% |
| 2011-09-30 | $0.25B | $-0.04B | 172.32% |
| 2010-12-31 | $0.23B | $0.09B | 175.88% |
| 2010-09-30 | $0.20B | $-0.01B | 84.73% |
| 2009-12-31 | $0.16B | $0.51B | 35.29% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.123B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.305B | 26.89 |
| Boston Scientific (BSX) | United States | $152.872B | 36.46 |
| Stryker (SYK) | United States | $146.007B | 29.72 |
| EssilorLuxottica (ESLOY) | France | $145.127B | 0.00 |
| Medtronic (MDT) | Ireland | $119.233B | 16.91 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.282B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.313B | 24.74 |
| ResMed (RMD) | United States | $41.712B | 29.83 |
| Agilent Technologies (A) | United States | $33.861B | 22.07 |
| GE HealthCare Technologies (GEHC) | United States | $33.512B | 15.75 |
| Terumo (TRUMY) | Japan | $27.642B | 32.75 |
| Koninklijke Philips (PHG) | Netherlands | $26.451B | 17.50 |
| Insulet (PODD) | United States | $22.615B | 75.77 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.354B | 12.96 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.855B | 0.00 |
| Baxter (BAX) | United States | $12.419B | 9.60 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.731B | 28.40 |
| Lantheus Holdings (LNTH) | United States | $3.684B | 9.96 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.430B | 24.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.198B | 14.19 |
| ICU Medical (ICUI) | United States | $2.986B | 20.33 |
| Haemonetics (HAE) | United States | $2.589B | 11.56 |
| LeMaitre Vascular (LMAT) | United States | $2.171B | 46.56 |
| Curaleaf Holdings (CURLF) | Canada | $1.782B | 0.00 |
| AtriCure (ATRC) | United States | $1.762B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.761B | 11.08 |
| Green Thumb Industries (GTBIF) | United States | $1.601B | 68.73 |
| AdaptHealth (AHCO) | United States | $1.283B | 18.24 |
| Phibro Animal Health (PAHC) | United States | $1.243B | 15.89 |
| Acuren (TIC) | United States | $1.190B | 0.00 |
| Neogen (NEOG) | United States | $1.179B | 18.72 |
| BioLife Solutions (BLFS) | United States | $1.166B | 2434.00 |
| Tilray Brands (TLRY) | Canada | $1.134B | 0.00 |
| Valneva SE (VALN) | France | $0.981B | 0.00 |
| InMode (INMD) | Israel | $0.907B | 8.39 |
| Kestra Medical Technologies (KMTS) | United States | $0.824B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.665B | 0.00 |
| Surmodics (SRDX) | United States | $0.536B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.49 |
| SNDL (SNDL) | Canada | $0.531B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.482B | 0.00 |
| CeriBell (CBLL) | United States | $0.451B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.451B | 15.53 |
| Owens & Minor (OMI) | United States | $0.439B | 3.89 |
| Verano Holdings (VRNOF) | United States | $0.438B | 0.00 |
| Evolus (EOLS) | United States | $0.435B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.364B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.331B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.330B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.312B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.287B | 0.00 |
| Omeros (OMER) | United States | $0.272B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 20.26 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.254B | 0.00 |
| Brainsway (BWAY) | Israel | $0.245B | 49.92 |
| Cerus (CERS) | United States | $0.238B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.234B | 0.00 |
| High Tide (HITI) | Canada | $0.216B | 0.00 |
| Quanterix (QTRX) | United States | $0.212B | 0.00 |
| Exagen (XGN) | United States | $0.209B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.202B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.83 |
| TriSalus Life Sciences (TLSI) | United States | $0.172B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.156B | 0.00 |
| Biote (BTMD) | United States | $0.144B | 4.79 |
| Jushi Holdings (JUSHF) | United States | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jin Medical (ZJYL) | China | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.08 |
| Quipt Home Medical (QIPT) | United States | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| Safety Shot (SHOT) | United States | $0.078B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.073B | 0.00 |
| Agape ATP (ATPC) | $0.063B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.055B | 32.12 |
| Veru (VERU) | United States | $0.053B | 0.00 |
| Zynex (ZYXI) | United States | $0.046B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 35.42 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 14.05 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.029B | 0.00 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |